Dermata Therapeutics Inc
DRMAW0.020USD
-0.005-21.88%
Close 04/24, 16:00（ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Dermata Therapeutics Inc Company
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.
Company Info
Company codeDRMAW
Company nameDermata Therapeutics Inc
IPO dateAug 13, 2021
Founded at2014
CEOMr. Gerald T. (Gerry) Proehl
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address3525 Del Mar Heights Rd., #322
CitySAN DIEGO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code92130
Phone18582230882
Websitehttps://www.dermatarx.com/
Company codeDRMAW
IPO dateAug 13, 2021
Founded at2014
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Kyri K. Van Hoose
Ms. Kyri K. Van Hoose
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Ms. Kathleen D. (Kathy) Scott
Ms. Kathleen D. (Kathy) Scott
Independent Director
Independent Director
--
--
Dr. Christopher J. Nardo, Ph.D.
Dr. Christopher J. Nardo, Ph.D.
Senior Vice President, Chief Development Officer
Senior Vice President, Chief Development Officer
--
--
Mr. Gerald T. (Gerry) Proehl
Mr. Gerald T. (Gerry) Proehl
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Mr. David F. Hale
Mr. David F. Hale
Lead Independent Director
Lead Independent Director
--
--
Dr. Steven J. Mento, Ph.D.
Dr. Steven J. Mento, Ph.D.
Independent Director
Independent Director
--
--
Dr. Maria Bedoya Toro Munera, Ph.D.
Dr. Maria Bedoya Toro Munera, Ph.D.
Senior Vice President - Regulatory Affairs & Quality Assurance
Senior Vice President - Regulatory Affairs & Quality Assurance
--
--
Ms. Mary M. Fisher
Ms. Mary M. Fisher
Independent Director
Independent Director
--
--
Dr. Andrew S. Sandler, M.D.
Dr. Andrew S. Sandler, M.D.
Independent Director
Independent Director
--
--
Ms. Brittany K. Bradrick
Ms. Brittany K. Bradrick
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Kyri K. Van Hoose
Ms. Kyri K. Van Hoose
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Ms. Kathleen D. (Kathy) Scott
Ms. Kathleen D. (Kathy) Scott
Independent Director
Independent Director
--
--
Dr. Christopher J. Nardo, Ph.D.
Dr. Christopher J. Nardo, Ph.D.
Senior Vice President, Chief Development Officer
Senior Vice President, Chief Development Officer
--
--
Mr. Gerald T. (Gerry) Proehl
Mr. Gerald T. (Gerry) Proehl
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Mr. David F. Hale
Mr. David F. Hale
Lead Independent Director
Lead Independent Director
--
--
Dr. Steven J. Mento, Ph.D.
Dr. Steven J. Mento, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholder
Update time: Sun, Feb 23
Update time: Sun, Feb 23
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Other
100.00%
Shareholder Statistics
Shareholder
Proportion
Other
100.00%
Type
Shareholder
Proportion
Other
100.00%
Institutional Shareholding
Update time: Mon, Mar 3
Update time: Mon, Mar 3
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
6
30.45K
0.00%
-15.89K
2024Q4
6
30.45K
0.00%
-15.89K
2024Q3
5
16.34K
0.00%
-51.21K
2024Q2
6
222.24K
0.00%
-16.66K
2024Q1
6
238.90K
0.00%
-306.46K
2023Q4
6
545.35K
0.00%
+302.33K
2023Q3
6
242.92K
0.00%
+5.51K
2023Q2
6
237.31K
0.00%
-9.97K
2023Q1
6
247.28K
0.00%
-332.43K
2022Q4
6
579.72K
0.00%
-41.18K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Two Sigma Investments, LP
12.86K
0%
+12.86K
--
Dec 31, 2024
Boothbay Fund Management, LLC
12.00K
0%
--
--
Dec 31, 2024
UBS Financial Services, Inc.
4.14K
0%
-100.00
-2.36%
Dec 31, 2024
Armistice Capital LLC
1.35K
0%
+1.35K
--
Dec 31, 2024
BofA Global Research (US)
100.00
0%
--
--
Dec 31, 2024
Warberg Asset Management LLC
--
0%
-30.00K
-100.00%
Sep 30, 2024
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data